AGC5201
5201 logo
Fair Value
JP¥7.6k
Share price07 Jul
JP¥6.42k15.5% undervalued intrinsic discount
Loading
1Y47.57%
7D-7.75%

5201: Panel Manufacturing Advances And Steady Metrics Will Shape Market Direction

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
03 Aug 25
Updated
07 Jul 26
Views
97
Not Invested

Last Update 07 Jul 26

Fair value Increased 3.05%

5201: Circular Fluorine Progress And 2026 Plan Will Support Upside Potential

Analysts have raised their price target on AGC to ¥7,598.75 from ¥7,373.75. This reflects updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, even though recent Street research has not introduced new company-specific catalysts.

What’s in the News for AGC

  • AGC completed third-party verification under UL 2809 for the fluorine raw materials used in AFLAS FFKM, confirming that 100% of the fluorine content allocated under the mass balance approach is attributed to recycled fluorite, supporting the company’s circular fluorine resource efforts. [Source: Company key development]
  • AFLAS FFKM, an industrial elastomer used in demanding semiconductor manufacturing applications, is now prepared to be offered as a product that combines high performance with environmental considerations. This aligns with AGC’s AGC plus 2026 mid-term plan focus on sustainability management. [Source: Company key development]
  • AGC Biologics joined OTXL’s Orphan ClinDevNet as a manufacturing partner, expanding collaboration to support end-to-end manufacturing for cell and gene therapies targeting ultra-rare conditions and providing broader geographic reach to patients and treatment centers. [Source: Client announcement]
  • Novelty Nobility expanded its manufacturing agreement with AGC Biologics to advance a bispecific antibody drug candidate through process development and GMP manufacturing at AGC Biologics’ Chiba facility, following cell line development in Copenhagen. Additional capacity is planned via a new single-use bioreactor facility in Yokohama. [Source: Client announcement]

Valuation Changes for AGC

  • Fair Value: The updated price target for AGC is ¥7,598.75, compared with the previous ¥7,373.75, reflecting a modest upward adjustment in the model inputs.
  • Discount Rate: The discount rate assumption is now 7.64%, compared with 7.60% previously, indicating a small change in the required return used in the valuation.
  • Revenue Growth: The long term revenue growth input is now 3.91%, compared with 3.92% before, implying a very slight adjustment to top line expectations in the model.
  • Net Profit Margin: The net profit margin assumption is now 5.14%, compared with 5.14% previously, indicating only a minimal change in projected profitability for AGC.
  • Future P/E: The future P/E multiple is now 16.61x, compared with 16.11x, suggesting a slightly higher valuation multiple applied to AGC’s forward earnings in the model.
0 viewsusers have viewed this narrative update

Key Takeaways

  • Advancements in product offerings, manufacturing expansion, and strategic exits are set to improve AGC's margins, profitability, and growth capacity across core business segments.
  • Rising global demand for energy-efficient and technologically advanced glass, driven by regulations and urbanization, provides sustained tailwinds for long-term revenue and earnings growth.
  • Weak demand, pricing pressures, challenging profitability in new ventures, and high capital intensity threaten AGC's revenue growth, margins, and investor confidence.

Catalysts

About AGC
    Manufactures and sells glass, electronics, chemicals, automotive, and ceramics worldwide.
What are the underlying business or industry changes driving this perspective?
  • The company is poised to benefit from a medium-term demand recovery in architectural glass, supported by increasing requirements for energy-efficient renovations in Japan and a likely rebound in Asian markets, which should drive higher shipment volumes and improved pricing, positively impacting revenue and operating profit.
  • AGC is advancing product mix upgrades in automotive and electronics (including smart technologies and value-added glass), leveraging R&D investments and pricing policies that are already beginning to yield better margins and are expected to enhance both gross and net margins over the coming cycles.
  • Expanded production capacity in Southeast Asia, especially in Chemicals (chlor-alkali, PVC), positions AGC to capture greater market share in regions with structural supply constraints, supporting higher top-line growth and scale-driven margin expansion.
  • Structural reforms and the strategic exit from loss-making U.S. biopharmaceutical operations will eliminate a major drag on profits, while refocusing Life Science on high-growth, single-use bag (SUB) technologies is expected to restore segment profitability and drive new growth from 2026 onward, directly benefitting net income.
  • Continued global trends toward sustainable, resilient construction and increased demand for advanced glass in smart, energy-efficient, and climate-adaptive buildings (driven by tighter regulations and urbanization in emerging markets) offer a structural tailwind to AGC's core businesses, underpinning long-term growth in both revenue and earnings.
AGC Earnings and Revenue Growth

AGC Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming AGC's revenue will grow by 3.9% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 4.1% today to 5.1% in 3 years time.
  • Analysts expect earnings to reach ¥120.9 billion (and earnings per share of ¥569.66) by about July 2029, up from ¥85.4 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as ¥136.4 billion.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 16.7x on those 2029 earnings, up from 16.3x today. This future PE is greater than the current PE for the JP Building industry at 13.1x.
  • Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.64%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Persistent weakness in demand and falling prices for key products, especially in the Asia region for architectural glass and for PVC in the Chemicals segment, due to factors like economic downturn in Europe and excess supply from China, will continue to pressure AGC's revenues and operating profit.
  • Structural and recurring losses in the Life Science/biopharmaceutical CDMO business-including unresolved production issues and heavy reliance on small and early-stage biotech clients-suggest ongoing challenges with profitability and cash flow in what is intended to be a future growth pillar.
  • Continued underperformance versus forecast (four years of operating profit and ROE below targets, with ROE under 5%), and frequent downward revisions in segment outlooks indicate difficulty in accurately forecasting and managing business cycles, which could erode investor confidence and depress valuation multiples.
  • Heightened competition and deteriorating price environment in key markets such as Indonesia and Thailand, and in electronic materials (e.g., EUV mask blanks), threaten AGC's pricing power and market share in both traditional and advanced product categories, directly impacting future revenue growth.
  • High capital intensity and limited ability to flex costs downward during periods of weak demand (noted through slow ramp-up of capacity expansions and sluggish returns from prior investments) expose AGC to sustained margin compression and subpar returns on equity and assets.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of ¥7598.75 for AGC based on their expectations of its future earnings growth, profit margins and other risk factors.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be ¥2352.7 billion, earnings will come to ¥120.9 billion, and it would be trading on a PE ratio of 16.7x, assuming you use a discount rate of 7.6%.
  • Given the current share price of ¥6556.0, the analyst price target of ¥7598.75 is 13.7% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on AGC?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

JP¥5k
FV
28.4% overvalued intrinsic discount
2.50%
Revenue growth p.a.
2
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
JP¥6.8k
FV
5.6% undervalued intrinsic discount
3.39%
Revenue growth p.a.
7
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Fair Value vs Share Price

JP¥7.6k
vs JP¥6.42k15.5% undervalued intrinsic discount
PastFuture-89b2t2015201820212024202620272029Revenue JP¥2.4tEarnings JP¥120.9b
3.9%
Revenue growth
5.1%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on AGC

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet, good value and pays a dividend.

Market capJP¥1.4t
PB0.9x
Estimated Growth3.1%
Dividend Yield3.3%
Full analysis

CEO & management

Yoshinori Hirai
CEO
4.8yrs
CEO Tenure

Manufactures and sells architectural glass, electronics, chemicals, automotive, and ceramics worldwide.